Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker
Jan 8, 2025 · Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent …
UBS raises Novo Nordisk stock rating to buy, cuts price target
Jan 8, 2025 · On Wednesday, UBS analyst Jo Walton upgraded Novo Nordisk (NYSE: NVO) stock from a Sell to a Buy rating, though the price target was adjusted to DKK750.00 from the …
Novo Nordisk Received an Upgrade from UBS for Its Ozempic …
Jan 8, 2025 · Despite Trump's tariff threat to Denmark and recent underwhelming trial data for Novo Nordisk's experimental obesity drug Carigsema, an upgrade came to Novo Nordisk from …
NVO Stock Up 3% as UBS Upgrades Company Rating From …
Jan 9, 2025 · Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off ...
Jan 8, 2025 · Investing.com - Novo Nordisk (CSE: NOVOb) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near …
Novo Nordisk upgraded to Buy from Neutral at UBS, as …
Jan 8, 2025 · UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high …
Novo Nordisk: UBS confirms its recommendation on the stock
Jan 14, 2025 · UBS remains Buy on the stock, with an unchanged target price of DKK 750 - a target implying a 19% upside potential for the pharmaceutical company's shares.'As expected, …
Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at UBS Group
Jan 10, 2025 · Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a “buy” rating in a research note issued to …
UBS Remains a Buy on Novo Nordisk (0QIU) | Markets Insider
5 days ago · UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed yesterday at …
UBS sees 'attractive entry point' in Novo Nordisk, stock lifts
Jan 8, 2025 · UBS argues that the current price level of Novo Nordisk offers an "attractive entry point" after "excessive" price pressure. The analysis also states that Novo Nordisk is "well …